New research presented this month at the American Society of Echocardiography meeting in Washington, DC, indicates that the use of microbubble contrast agents with ultrasound scans of the heart can work to break up blood clots that cause strokes
New research presented this month at the American Society of Echocardiography meeting in Washington, DC, indicates that the use of microbubble contrast agents with ultrasound scans of the heart can work to break up blood clots that cause strokes and heart attacks. In a study presented June 14 at the ASEs 10th annual scientific sessions, University of Nebraska Medical Center researchers compared the efficacy of ultrasound scans alone to ultrasound scans with an injection of perfluorocarbon microbubbles. Dr. Thomas Porter and colleagues discovered that adding the contrast to cardiac ultrasound therapy scans helped to dissolve blood clots.
Porter and his team did their research by producing a laboratory simulation of blood vessels with clots using tubing, saline, and clots gathered from pigs. Porter explained that the combination of ultrasound waves and microbubbles increased motion around the clots, causing them to fragment. The study points to another nonsurgical method of dispelling clots that lead to stroke or heart attack.
© 1999 Miller Freeman, Inc.All rights reserved.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.